CTX-712

• UNSPSC Description:

  CTX-712 is an orally effective CLK 2 inhibitor, with an IC50 of 1.4 nM, showing anti-tumor activity[1][2].

• Target Antigen:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ctx-712.html

• Solubility:

  DMSO : 25 mg/mL (ultrasonic)

• Smiles:

  CC1=NC2=NC=C(C3=C4C(OC)=NC=NN4C=C3)C=C2N1CC5=NN=C([C@H](F)C)O5

• Molecular Weight:

  408.39

• References & Citations:

  [1]Akinori Yoda, et al. CTX-712, a Novel Clk Inhibitor Targeting Myeloid Neoplasms with SRSF2 Mutation. Blood. (2021) 205–206 |[2]Zhen Qin, et al. Development of Cdc2-like Kinase 2 Inhibitors: Achievements and Future Directions. J Med Chem. 2021 Sep 23;64(18):13191-13211.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Phase 2

• CAS Number:

  2144751-78-8